Appili Therapeutics launches new oral suspension drugs, secures funding, and advances vaccine and antiparasitic products.

From GlobeNewswire: 2025-06-25 18:04:00

Appili Therapeutics has re-launched LIKMEZ™ (ATI-1501) metronidazole oral suspension in the U.S., providing a new treatment option for patients who have difficulty swallowing tablets. The company has also submitted five funding proposals to the U.S. government, totaling up to US$125 million. Additionally, ATI-1701, a biodefense vaccine candidate, has received funding from the U.S. Air Force Academy and has shown promising results in protecting against tularemia. Appili is also advancing ATI-1801, a topical antiparasitic product, with positive Phase 3 study data and potential for FDA priority review.

Appili Therapeutics has successfully re-launched LIKMEZ™ (ATI-1501) metronidazole oral suspension in the U.S., providing a new treatment option for patients with difficulty swallowing tablets. The company has also submitted five funding proposals to the U.S. government, totaling up to US$125 million, to support the development of infectious disease products. Additionally, ATI-1701, a biodefense vaccine candidate, has received funding from the U.S. Air Force Academy and shown positive results in protecting against tularemia. Appili is also advancing ATI-1801, a topical antiparasitic product, with promising Phase 3 study data and potential FDA priority review.



Read more at GlobeNewswire: Appili Therapeutics Reports Fiscal Year 2025 Financial and